GlassScriptPhysician profile
Crystal R Threadgill
NPI 1528500907
$2,728.85
in general payments reported to CMS, 2019-2025
19 companies · $584 in 2025
The $584 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $712 · 2022: $672 · 2023: $379 · 2024: $382 · 2025: $584.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,345.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,344.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,272.67 | 2021-2025 | |
| Alkermes, INC. | $302.55 | 2022-2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $289.11 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $172.62 | 2021-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $134.38 | 2021-2025 | Spravato |
| Lundbeck LLC | $101.03 | 2023-2025 | Rexulti, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $96.63 | 2022-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $95.05 | 2021-2024 | Trintellix |
| Indivior INC. | $41.98 | 2024 | Sublocade |
| Neurocrine Biosciences, INC. | $41.94 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $34.76 | 2025 | Cobenfy |
| Neos Therapeutics, LP | $24.80 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $22.49 | 2021 | |
| Bausch Health US, LLC | $22.25 | 2023 | Wellbutrin, Aplenzin |
| Almatica Pharma LLC | $20.50 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $15.88 | 2023 | Azstarys |
| Alfasigma USA, INC. | $14.31 | 2021 | |
| Supernus Pharmaceuticals, INC. | $13.95 | 2023 | Qelbree |
| Merck Sharp & Dohme LLC | $11.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Crystal Threadgill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.